Short answer
Maze Therapeutics, Inc. (MAZE) filed an 8-K current report with the SEC on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.
Maze Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release issued August 11, 2026
- Detailed financial figures and management commentary available in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q2 net loss $44.7M, or $0.76 per share, versus $33.7M and $0.77 in Q2 2025
- Cash, equivalents and marketable securities $494.9M, supporting operations into 2029 under current plans
- MZE829 HORIZON enrollment ongoing; updated data from three 10–15-patient cohorts expected late 2026 or early 2027
- Pivotal MZE829 trial targeted for H1 2027, subject to regulatory feedback
- MZE782 PKU Phase 2 underway with 2027 data; CKD Phase 2 initiation planned for H1 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Maze Therapeutics, Inc. 8-K filings
Get the next MAZE 8-K as it lands
Follow MAZE for push alerts, or ask the research agent what this filing means.